AVANIR Pharmaceuticals, Inc. (AVNR) Receives U.S. Patent for Zenvia™
AVANIR Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders, recently announced that the company has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) for its lead drug candidate Zenvia™, a treatment pseudobulbar affect (PBA). This patent will provide AVANIR Pharmaceuticals commercial exclusivity for PBA indication well into 2025. AVANIR Pharmaceuticals also has exclusive rights to other patents and patent applications for treating PBA, chronic pain and other neurologic conditions using combinations of dextromethorphan and quinidine. Greg Flesher, vice president of…